Evidence map›Paper›PMID 26347629›Full record

ArticleFrontiers in behavioral neuroscience2015

Differential effects of wake promoting drug modafinil in aversive learning paradigms.

Bharanidharan Shanmugasundaram, Volker Korz, Markus Fendt, Katharina Braun, Gert Lubec

Open access · goldAbstract read
In one paragraph

Article in Frontiers in behavioral neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Bharanidharan ShanmugasundaramDepartment of Pharmaceutical Chemistry, University of Vienna Vienna, Austria.
Volker KorzDepartment of Pharmaceutical Chemistry, University of Vienna Vienna, Austria.
Markus FendtInstitute for Pharmacology and Toxicology, and Center for Behavioral Brain Sciences, Otto-von-Guericke University Magdeburg Magdeburg, Germany.
Katharina BraunDepartment of Zoology/Developmental Neurobiology, Institute of Biology, Otto-von-Guericke University Magdeburg Magdeburg, Germany.
Gert LubecDepartment of Pharmaceutical Chemistry, University of Vienna Vienna, Austria.
University of Vienna · ATOtto-von-Guericke University Magdeburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modafinil (MO) an inhibitor of the dopamine transporter was initially approved to treat narcolepsy, a sleep related disorder in humans. One interesting "side-effect" of this drug, which emerged from preclinical and clinical studies, is the facilitation of cognitive performance. So far, this was primarily shown in appetitive learning paradigms, but it is yet unclear whether MO exerts a more general cognitive enhancement effect. Thus, the aim of the present study in rats was to extend these findings by testing the effects of MO in two aversive paradigms, Pavlovian fear conditioning (FC) and the operant two-way active avoidance (TWA) learning paradigms. We discovered a differential, task-dependent effect of MO. In the FC paradigm MO treated rats showed a dose-dependent enhancement of fear memory compared to vehicle treated rats, indicated by increased context-related freezing. Cue related fear memory remained unaffected. In the TWA paradigm MO induced a significant decrease of avoidance responses compared to vehicle treated animals, while the number of escape reactions during the acquisition of the TWA task remained unaffected. These findings expand the knowledge in the regulation of cognitive abilities and may contribute to the understanding of the contraindicative effects of MO in anxiety related mental disorders.

Indexed as

aversive learningcognitive enhancerfear conditioningfeedback learningtwo-way active avoidance

Identifiers

PMID26347629
PMCPMC4541287
OpenAlexW1515657681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.